Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S.

Diabetes Care

Volumn 26, Issue 8, 2003, Pages 2305-2310

  Shearer, Arran ^a   Scuffham, Paul ^a   Gordois, Adam ^a   Oglesby, Alan ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; FEMALE; FOOT ULCER; HIGH RISK PATIENT; HUMAN; MALE; MONTE CARLO METHOD; OUTCOMES RESEARCH; PERCEPTIVE THRESHOLD; PERIPHERAL NEUROPATHY; PREDICTION; QUALITY ADJUSTED LIFE YEAR; WHOLE BODY VIBRATION;

AGED; AMPUTATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; DIABETIC NEUROPATHIES; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; MONTE CARLO METHOD; PREDICTIVE VALUE OF TESTS; UNITED STATES; VIBRATION;

EID: 0042524668     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.8.2305     Document Type: Article

References (35)

1. Boulton A: The diabetic foot: a global view. Diabete Metab Res Rev 16:S2-S5, 2000
2. Gonzalez ER, Oley MA: The management of lower-extremity diabetic ulcers. Manag Care Interface 13:80-87, 2000
3. Reiber GE, Vileikyte L, Boyko EJ, Del Aguila M, Smith DG, Lavery LA, Boulton AJM: Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 22:157-162, 1999
4. Mancini L, Ruotolo V: The diabetic foot: epidemiology. Rays 22:511-523, 1997
5. Spencer S: Pressure Relieving Interventions for Preventing and Treating Diabetic Foot Ulcers. Issue 1. The Cochrane Library. Oxford, U.K., Update Software, 2002
6. Kantor J, Margolis DJ: Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatologic Surg 27:347-351, 2001
7. Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA: Lower extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care 12:24-31, 1989
8. Gordois A, Scuffham P, Shearer A, Oglesby A: The health care costs of peripheral neuropathy for people with diabetes in the U.S. Diabetes Care 26:1790-1795, 2003
9. Grunert BK, Wertsch JJ, Matloub HS, McCallum-Burke S: Reliability of sensory threshold measurement using a digital Vibrogram. J Occup Med 32:100-102, 1990
10. Dyck PJ, Larson TS, O'Brien PC, Velosa JA: Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts: the Nerve Growth Factor Study Group. Diabetes Care 23:510-517, 2000
11. Young MJ, Breddy JL, Veves A, Boulton AJ: The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds: a prospective study. Diabetes Care 17:557-560, 1994
12. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ: Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 21:1071-1075, 1998
13. Coppini DV, Young PJ, Weng C, Macleod AF, Sonksen PH: Outcome on diabetic foot complications in relation to clinical examination and quantitative sensory testing: a case-control study. Diabet Med 15:65-771, 1998
14. Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A: Screening techniques to identify people at high risk for diabetic foot ulceration. Diabetes Care 23:606-611, 2000
15. Canadian Coordinating Office of Health Technology Assessment (CCOHTA): Guidelines for Economic Evaluation of Pharmaceuticals: Canada. Ottawa, Canada, CCOHTA, 1994
16. Commonwealth Department of Human Services and Health: Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia, Australian Government Publishing Service, 1995
17. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
18. National Institute for Clinical Excellence: Technical Guidance for Manufacturers and Sponsors on Making a Submission to a Technology Appraisal. London, National Institute for Clinical Excellence, 2001
19. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 13:322-338, 1993
20. Allenet B, Paree F, Lebrun T, Carr L, Posnett J, Martini J, Yvon C: Cost-effectiveness modelling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab 26:125-132, 2000
21. Holzer SE, Canerota A, Martens L, Cuerdon T, Crystal-Peters J, Zagari M: Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 20:169-181, 1998
22. Moss SE, Klein R, Klein B: The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 152:610-616, 1992
23. Rossing P, Hougaard P, Borch-Johnsen K, Parving H: Predictors of mortality in insulin dependent diabetes: 10-year observational follow up study. BMJ 313:779-784, 1996
24. Geiss LS, Herman WH, Smith PJ: Mortality in non-insulin dependent diabetes. In Diabetes In America. 2nd ed. National Diabetes Data Group, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Disease, Eds. Washington, DC, U.S. Govt. Printing Office, 1995, p. 233-257 (NIH 95-1468)
25. Boyko EJ, Ahroni JH, Smith DG, Davignon D: Increased mortality associated with diabetic foot ulcer. Diabet Med 13:967-972, 1996
26. Apelqvist J, Larsson J, Agardh CD: Long-term prognosis for diabetic patients with foot ulcers. J Intern Med 233:485-491, 1993
27. Faglia E, Favales F, Morabito A: New ulceration, new major amputation, and survival rates in diabetic subjects hospitalized for foot ulceration from 1990 to 1993: a 6.5-year follow-up. Diabetes Care 24:78-83, 2001
28. Carrington AL, Mawdsley SKV, Morley M, Kincey J, Boulton AJM: Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 32:19-25, 1996
29. Allowance for differential timing of costs (discounting and the annuization of capital expenditure). In Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Drummond MF, O'Brien B, Stoddart GL, Torrance G, Eds. New York, Oxford University Press, 1997, p. 68-74
30. Drummond MF, O'Brien B, Stoddart GL, Torrance G (Eds): Should effects occurring in the future be discounted? In Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York, Oxford University Press, 1997, p. 107-109
31. Lipscomb J, Weinstein MC, Torrance GW: Time Preference. In Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC, Eds. New York, Oxford University Press, 1996, p. 214-246
32. Greene WH: Computation and Optimization. In Econometric Analysis. 3rd ed. Greene WH, Ed. New York, Prentice-Hall International, 1997, p. 173-219
33. TreeAge Software I: Performing Monte Carlo simulation. In Data 4.0: HealthCare User's Manual. Williamstown, MA, TreeAge Software, 2001, p. 293-311
34. The Centers for Disease Control Diabetes Cost-Effectiveness Study Group: The cost-effectiveness of screening for type 2 diabetes. JAMA 280:1757-1763, 1998
35. Calle-Pascual AL, Durán A, Benedi A, Calvo MI, Charro A, Diaz JA, Calle JR, Gil E, Maranes JP, Cabezas-Cerrato J: A preventive foot care programme for people with diabetes with different stages of neuropathy. Diabetes Res Clin Pract 57:111-117, 2002